Navigation Links
WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
Date:2/5/2009

SHANGHAI, China, Feb. 5 /PRNewswire-Asia/ - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced the addition of Stewart Hen and Ning Zhao to the WuXi PharmaTech Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Ge Li, WuXi's Chairman and Chief Executive Officer, commented, ''We welcome the addition of Stewart Hen and Ning Zhao to the board. Each brings invaluable expertise as we work to anticipate and meet our customers' evolving needs for improving R&D productivity.''

Mr. Hen is a managing director at Warburg Pincus LLC, a leading global private equity firm. He focuses on investments in biotechnology and pharmaceuticals, including pharmaceutical outsourcing. Mr. Hen has more than 17 years of experience in the life sciences industry. Prior to Warburg Pincus, he was a consultant at McKinsey & Company serving the pharmaceutical industry. Previously, he worked at Merck in both research and development and manufacturing. Mr. Hen holds an M.B.A. from the Wharton School of the University of Pennsylvania and an M.S. in chemical engineering from the Massachusetts Institute of Technology.

Dr. Zhao, one of WuXi's co-founders, is currently lead advisor to the company's analytical services operations. She was vice president of WuXi's analytical department from 2004 to 2008 and also established its Bio-Analytical Services, Core Analytical Services, and Analytical Development Services departments. She previously worked for Wyeth as a senior research scientist, for Pharmacopeia as a group leader for the high-throughput analysis of combinatorial libraries, and for Bristol-Myers Squibb as a site leader in the Discovery Analytical Sciences department. Dr. Zhao is the co-inventor of numerous patents and has published and presented more than 36 scientific papers. With more than 10 years' experience in analytical sciences in the U.S. pharmaceutical industry, she has received numerous awards, including the 2002 Chemistry Leadership Award from Bristol-Myers Squibb and the 1995 Pegram Award from Columbia University, where she received her Ph.D. Dr. Zhao is married to Dr. Li.

Separately, WuXi announced that Mr. Tao Lin, the company's Vice President of Internal Operations since 2002 and a director of the company since 2005, has resigned from the board of directors and as a company officer for personal reasons. Mr. Lin was one of the founders of the company.

''I want to personally thank Tao for his counsel and wisdom while serving on our board,'' said Dr. Li. ''As a founder and key executive of the company, Tao made many contributions to build WuXi from a start-up to the strong company we are today. We all wish him well.''

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-215-218-5515
     Email: ir@wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
2. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
3. WuXi PharmaTech Announces Second Quarter 2008 Results
4. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
5. Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
6. WuXi PharmaTech 2007 Annual Report Available Online
7. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
8. Stanford Professor Barry M. Trost Visits WuXi PharmaTech and Gives Two Seminars
9. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
10. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
11. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider ... that a new solution for Emergency Departments (ED) has been added to their ... Emergency Department examination rooms, and with a simplified pallet of information available to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority ... care and patient safety. Only a few hospitals and facilities have earned this ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... the largest share of the market in 2016 and ... dominance can be attributed to a large number of ... (US hold the largest share in the patient temperature ... benefits such as reducing loss of blood during surgeries, ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology: